Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10240332 | 1.00 | ALDH1A1 (0.41) | ALDH1A1NPSR1L3MBTL1CRHBPCRHR2 | |
| Hydrochloric Acid SCHEMBL624484 | 0.99 | ALDH1A1 (0.40) | ALDH1A1NPSR1L3MBTL1CRHBPCRHR2 | |
| SCHEMBL10189406 | 0.95 | ALDH1A1 (0.39) | ALDH1A1NPSR1L3MBTL1CRHBPCRHR2 | |
| SCHEMBL10189408 | 0.95 | ALDH1A1 (0.39) | ALDH1A1NPSR1L3MBTL1CRHBPCRHR2 | |
| SCHEMBL617444 | 0.88 | LMNA (0.40) | ALDH1A1AAK1RXFP1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL616095 | 0.87 | LMNA (0.40) | ALDH1A1AAK1RXFP1LMNAMAPT | |
| SCHEMBL3298400 | 0.87 | ROCK2 (0.45) | ALDH1A1NPSR1L3MBTL1AAK1RXFP1 | |
| Hydrochloric Acid SCHEMBL616411 | 0.86 | ROCK2 (0.45) | ALDH1A1NPSR1AAK1RXFP1MAPT | |
| SCHEMBL10241739 | 0.86 | LMNA (0.41) | ALDH1A1AAK1RXFP1LMNAMAPT | |
| SCHEMBL10242402 | 0.86 | LMNA (0.39) | ALDH1A1AAK1RXFP1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-8058297-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058297-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN | 2009-10-29 | — | — | US | disclosed |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN | 2009-10-29 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | RB1, MKI67, MAPRE1 | ALDH1A1 1872/4885NPSR1 1837/4885L3MBTL1 3887/4885 |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | ALDH1A1 1872/4885NPSR1 1837/4885L3MBTL1 3887/4885 |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | ALDH1A1 1872/4885NPSR1 1837/4885L3MBTL1 3887/4885 |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | ALDH1A1 1872/4885NPSR1 1837/4885L3MBTL1 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.